Company profile
Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Aldastotug | phase1 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05720117 | phase1 | recruiting | 2023-03-14 | 2027-04-25 | Pyxis Oncology, Inc | A Study of PYX-201 in Advanced Solid Tumors |
| NCT06795412 | phase1_2 | recruiting | 2025-04-15 | 2027-12-06 | Pyxis Oncology, Inc | Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors |
| NCT05718557 | phase1 | active_not_recruiting | 2023-05-23 | 2026-05-01 | Pyxis Oncology, Inc | Study of PYX-106 in Solid Tumors |
FDA applications (0)
No records yet.